A Study to Test if Fremanezumab is Effective in Preventing Episodic Migraine in Patients 6 to 17 Years of Age

Study Title
A Study to Test if Fremanezumab is Effective in Preventing Episodic Migraine in Patients 6 to 17 Years of Age
Teva Identifier
TV48125-CNS-30083
ClinicalTrials.gov Identifier
NCT04458857
Study Status
Completed
Trial Condition(s)
Migraine
Interventions
Drug: Fremanezumab | Drug: Placebo
EudraCT Number
2019-002055-42
Study Description
Please refer to ClinicalTrials.gov for a description of the trial
headache-icon

Key Participation Requirements

Gender
Female, Male
Age group
Child
Age Range
6 Years to 17 Years
Trial Duration
July 15, 2020 - March 13, 2024
Phase
Phase 3

Additional info

Study Type

Interventional